NASDAQ:PTCT

Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy

- Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app - SYDNEY, Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company's 2023 STRI...

2023-09-07 20:00 1808

Week's Top Stories